Allied Market Research
image  Direct : +1 (617) 674-4143 | Toll Free : +1 (855) 711-1555


Report Image
Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020
Published: Jan-2014    |    Formats: PDF & Excel   |   Author(s):Debbie Shields and Roshan Deshmukh   |   Code: DI 14114
  • Report
    Overview
  • Table of
    Contents
  • Research
    Methodology
  • Analyst's
    Review
  • Sample

Pages 148
Tables 67

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.

Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

KEY BENEFITS

  • This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell market
  • Detailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decision
  • Value chain analysis, Porter’s five forces, top investment pockets are analysed and presented in detail in the report
  • Intelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisions
  • SWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.

KEY MARKET SEGMENTS

GLOBAL MARKET, BY STORAGE

  • Public cord blood banks
  • Private cord blood banks
  • Public Vs. Private UCB banks

GLOBAL MARKET, BY DISEASES

  • Cancer/ Oncology diseases
  • Acute Leukemia
  • Chronic Leukemia
  • High Risk Solid Tumors
  • Myelodysplastic Syndrome
  • Blood diseases
  • Aplastic Anemia
  • Beta Thalassemia
  • Sickle Cell disease     
  • Immune Disorders
  • Leukocyte Adhesion Deficiency
  • Hystiocytic Disorders
  • Wiskott-Aldrich
  • Metabolic Disorders
  • Krabbe Disease
  • Hurler Syndrome
  • Sanfilippo Syndrome
  • Other diseases
  • Osteopetrosis
  • Hemophagoyticlymphohistiocytosis

GLOBAL MARKET BY, TECHNOLOGY

  • Stem Cell Transplant
  • Autologous transplant
  • Allogenic transplant
  • Transplant Medicine
  • Regenerative Medicine
  • Others
  • Cord Blood Banking
  • Blood Transfusion
  • Cell Based Genetics

GLOBAL MARKET, BY GEOGRAPHY

  • UCB market in North America
  • UCB market in Europe
  • UCB market in Asia-pacific
  • UCB market in ROW

KEY AUDIENCES

  • Therapeutics service companies
  • Private and government research institutes
  • Academic Institutes
  • Research based pharmaceutical companies
  • Public and Private cord blood banks

CHAPTER 1 INTRODUCTION

1.1 Key objectives
1.2 Key benefits
1.3 Key deliverables
1.4 Key audiences

1.5 Research methodology

1.5.1 Secondary research
1.5.2 Primary research
1.5.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Umbilical cord blood stem cell market by Geography , 2012-2020, $million

CHAPTER 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW

3.1 Market Description
3.2 Market definition and Scope
3.3 Awareness programs for cord blood donation
3.4 Key findings

3.4.1 Top ten factors impacting UCB stem cell market

3.4.1.1 Minimal invasive techniques of collection and transferring
3.4.1.2 Efficient extraction of cord blood
3.4.1.3 Storage service for maintaining viability
3.4.1.4 Government regulation and intervention
3.4.1.5 Ethical issues in storage and application
3.4.1.6 Cost of treatment
3.4.1.7 Availability of treatment and sample
3.4.1.8 Positive engraftment of tissue
3.4.1.9 Efficient transferring during treatment
3.4.1.10 Reimbursement and insurance issues in storage

3.4.2 Top winning strategies
3.4.3 Top Investment pockets

3.4.3.1 UCB stem cell market - by Application
3.4.3.2 UCB market- by Therapeutics
3.4.3.3 UCB market- by Storage service

3.5 Advantages of umbilical cord blood stem cells over peripheral blood stem cells
3.6 Key advantages of UCB stem cells.

3.6.1 Prompt availability
3.6.2 Ease of collection
3.6.3 More tolerance for graft failure
3.6.4 Reduce risk of Graft vs. host disease (GVHD)
3.6.5 Decreased transmission of viral disease infection

3.7 Regulatory issues, legislations and authorities Reimbursement Issues

3.7.1 Regulatory issues of UCB stem cells storage and application (U.S.)

3.7.1.1 American Academy of Pediatrics (AAP)
3.7.1.2 American society for Blood and Marrow Transplantation (ASBMT)

3.7.2 Regulatory issues concenringUCB stem cells storage and application in European countries
3.7.3 Reimbursement issues

3.8 Ethical issues of stem cell therapies and cord blood banking

3.8.1 Ethical issues regarding cord blood banking
3.8.2 Ethical issues in cord blood stem cell therapies

3.9 Umbilical cord blood stem cell collection process
3.10 UCB Stem cells Storage and collection Outsourcing

3.10.1 Stem cell storage and collection outsourcing

3.10.1.1 Criteria for outsourcing of cord blood storage

3.11 Key patents and analysis of Novel Patents
3.12 Clinical trials in UCB stem cell market

3.12.1 Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetes
3.12.2 Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children
3.12.3 Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)
3.12.4 Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced-intensity Conditioning Regimen
3.12.5 Umbilical Cord Blood Transplant for Congenital Pediatrics Disorders

3.13 Value chain analysis of UCB stem cell market
3.14 Porter’s five forces analysis for cord blood stem cell market

3.14.1 Higher bargaining power of suppliers for getting competitive advantage
3.14.2 Lower bargaining power of buyers in terms of treatment
3.14.3 Higher degree of competition
3.14.4 Threats of new entrants increases due to novel therapies
3.14.5 Increased threats fromconventional therapies and banking substitutes

 3.15 Market Dynamics of UCB stem cell market

3.15.1 Market Drivers

3.15.1.1 Minimal invasive methods
3.15.1.2 Treatment on chronic diseases
3.15.1.3 Cost effective therapy and storage
3.15.1.4 Easy extraction methods
3.15.1.5 Intact genetic structure

3.15.2 Market Restraints

3.15.2.1 Government regulations and intervention
3.15.2.2 Legal and ethical issues during collection
3.15.2.3 Availability of right type of donor
3.15.2.4 Higher cost of therapies

3.15.3 Market Opportunities

3.15.3.1 Advancement in therapeutic application
3.15.3.2 Rising funds for public storage
3.15.3.3 Increase in cost effectiveness to increase APAC market presence

CHAPTER 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE

4.1 Difference between Public vs. Private UCB banks

4.1.1 Umbilical cord blood stem cell storage service market ,2012-2020, $million

4.2 Market Drivers

4.2.1 Lower cost structure
4.2.2 Immediate availability
4.2.3 Government Intervention
4.2.4 Decrease transplant complications

4.3 Market Restraints

4.3.1 Long term storage
4.3.2 Lower volume of blood
4.3.3 Operational Issues
4.3.4 Legal & Ethical Issues

4.4 Market Opportunities

4.4.1 Additional fund collection
4.4.2 Technological adoptions
4.4.3 Insurance as USP
4.4.4 Lowering healthcare costs

4.5 Public cord blood banks

4.5.1 Cost structure of public cord blood banking:
4.5.2 UCB public storage bank service market , 2012-2020, $million

4.6 Private cord blood banks

4.6.1 UCB private storage bank service market, 2012-2020, $million

CHAPTER 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS

5.1 Umbilical cord blood stem cell therapeutics market , 2012-2020, $million
5.2 Market Drivers

5.2.1 Fast recovery
5.2.2 Efficient transferring of stem cells
5.2.3 Minimum invasive technique
5.2.4 Target specific

5.3 Market Restraints

5.3.1 Higher cost of treatment
5.3.2 Scarcity of donor
5.3.3 Rejection in allogenictransplantation
5.3.4 Difficulty in donor matching

5.4 Opportunities

5.4.1 Increasing flexibility
5.4.2 Improved donor policy
5.4.3 Risk management

5.5 Cancer/ Oncology diseases

5.5.1 UCB stem cell cancer therapeutics geography market , 2012-2020, $million
5.5.2 UCB stem cell cancer therapeutics market , 2012-2020, $million
5.5.3 Acute Leukemia
5.5.4 UCB stem cell Acute leukemia therapeutics market , 2012-2020,$million
5.5.5 Chronic Leukemia
5.5.6 GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012-2020, $million
5.5.7 High risk solid tumours
5.5.8 Global UCB stem cell high risk solid tumor therapeutics market , 2012-2020, $million
5.5.9 Myelodysplastic syndrome
5.5.10 Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012-2020,$million
5.5.11 Others(chronic myelomonocyticleukemia (CMML))
5.5.12 UCB stem cell other disease therapeutics geography market , 2012-2020, $million

 5.6 Diabetes

5.6.1 Global UCB stem cell diabetes therapeutics market , 2012-2020, $million
5.6.2 Global UCB stem cell diabetes therapeutics geography market , 2012-2020, $million
5.6.3 Type 1 diabetes
5.6.4 Global UCB stem cell type I diabetes therapeutics geography market, 2012-2020, $million
5.6.5 Type 2 diabetes
5.6.6 UCB stem cell Type II diabetes therapeutics geography market , 2012-2020, $million
5.6.7 Others(Gestational Diabetes Mellitus (GDM)
5.6.8 UCB stem cell Gestational Diabetes Mellitus (GDM) therapeutics geography market , 2012-2020, $million

5.7 Blood diseases

5.7.1 UCB stem cell blood diseases therapeutics market , 2012-2020, $million
5.7.2 UCB stem cell blood diseases therapeutics geography market, 2012-2020, $million
5.7.3 Aplastic Anemia
5.7.4 Global UCB stem cell Aplastic anemia therapeutics geography market 2012-2020, $million
5.7.5 Beta Thalassemia
5.7.6 Global UCB stem cell Thalassemia therapeutics geography market , 2012-2020, $million
5.7.7 Sickle Cell disease
5.7.8 Global UCB stem cell Sickle cell disease therapeutics geography market 2012-2020, $million
5.7.9 Others (Iron deficiency anemia)
5.7.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million

5.8 Immune Disorders

5.8.1 Global UCB stem cell immune disorders therapeutics market , 2012-2020, $million
5.8.2 Global UCB stem cell immune disorders therapeutics geography market , 2012-2020, $million
5.8.3 Leukocyte Adhesion Deficiency
5.8.4 Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012-2020, $million
5.8.5 Hystiocytic disorders
5.8.6 Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012-2020, $million
5.8.7 Wiskott-Aldrich
5.8.8 Global UCB stem cell Wiskott-Aldrich therapeutics geography market 2012-2020, $million
5.8.9 Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS)
5.8.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million

5.9 Metabolic Disorders

5.9.1 Global UCB stem cell metabolic disorders therapeutics market , 2012-2020, $million
5.9.2 Global UCB stem cell metabolic disorders therapeutics geography market , 2012-2020, $million
5.9.3 Krabbe Disease
5.9.4 Global UCB stem cell Krabbe disease therapeutics geography market , 2012-2020, $million
5.9.5 Hurler Syndrome
5.9.6 Global UCB stem cell Hurler syndrome therapeutics geography market , 2012-2020, $million
5.9.7 Sanfilippo Syndrome
5.9.8 Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012-2020, $million
5.9.9 Others (Fabry disease)
5.9.10 Global UCB stem cell Fabry disease therapeutics geography market , 2012-2020, $million

5.10 Other diseases

5.10.1 Global UCB stem cell other disease therapeutics market 2012-2020, $million
5.10.2 Osteopetrosis
5.10.3 Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012-2020, $million
5.10.4 Hemophagoyticlymphohistiocytosis (HLH)
5.10.5 Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012-2020, $million

CHAPTER 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION

6.1 Umbilical cord blood stem cell application market , 2012-2020, $million
6.2 Drivers of UCB stem cell application market

6.2.1 Auto-repair process
6.2.2 Pre-surgery management
6.2.3 Disease information
6.2.4 Positive engraftment

6.3 Restraints of UCB stem cell application market

6.3.1 Higher cost of treatment
6.3.2 Genetic variation
6.3.3 Donor Matching
6.3.4 Ethical problem

6.4 Opportunity of UCB stem cell application market

6.4.1 Cost effective regenerative medicines
6.4.2 Wound management therapies
6.4.3 Growing research institute

6.5 Stem Cell Transplant

6.5.1 Global UCB stem cell transplant application market , 2012-2020, $million
6.5.2 Autologous transplant
6.5.3 Global UCB stem cell autologous transplant applicationgeogrpahy market 2012-2020, $million
6.5.4 Allogenictransplant
6.5.5 Global UCB stem cell allogenic transplant application geography market , 2012-2020, $million

6.6 Transplant Medicine

6.6.1 Global UCB stem cell transplant medicine application geography market , 2012-2020, $million

6.7 Regenerative Medicine

6.7.1 Global UCB stem cell regenerative medicine application geography market , 2012-2020, $million

6.8 Others

6.8.1 Global UCB stem cell other diseases application market , 2012-2020, $million
6.8.2 Blood Transfusion
6.8.3 Global UCB stem cell blood tranfusion application geography market 2012-2020, $million
6.8.4 Cell Based Genetics
6.8.5 Global UCB stem cell based genetics application geography market , 2012-2020, $million

CHAPTER 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY

7.1 Umbilical cord blood stem cell market by geography , 2012-2020, $million
7.2 UCB stem cell market in North America
7.3 UCB stem cell market in Europe
7.4 UCB stem cell market in Asia-Pacific
7.5 UCB market in ROW

CHAPTER 8 COMPANY PROFILES

8.1 Cytori Therapeutics Inc.

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Key Financials of Cytori Therapeutics Inc.
8.1.4 Key Strategies of Cytori Therapeutics Inc.

8.1.4.1 Primary Strategies: Approval
8.1.4.2 Secondary Strategies: Product Launch and Clinical trials

8.1.5 SWOT AnalysisofCytori Therapeutics Inc.

8.2 Advanced Cell Technology, Inc. (USA)

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Key Financials Advanced Cell Technology, Inc. (USA)
8.2.4 Key Strategies Advanced Cell Technology, Inc. (USA)

8.2.4.1 Primary Strategies: Approval
8.2.4.2 Secondary strategies: Study Report

8.2.5 SWOT Analysis Advanced Cell Technology, Inc. (USA)

8.3 California Stem Cell

8.3.1 Company Overview
8.3.2 Company Snapshot:
8.3.3 Key Strategies California Stem Cell

8.3.3.1 Primary Strategies: Approval
8.3.3.2 Secondary Strategies: Acquisition and clinical trials

8.3.4 SWOT Analysis of California Stem Cell

8.4 Osiris Therapeutics

8.4.1 Company Overview
8.4.2 Company Snapshot:
8.4.3 Key Financials Osiris Therapeutics
8.4.4 Key Strategies Osiris Therapeutics

8.4.4.1 Primary Strategies: Approval
8.4.4.2 Secondary strategies: Clinical Trials

8.4.5 SWOT analysis of Osiris therapeutics

8.5 NeoStem Inc.

8.5.1 Company Overview
8.5.2 Company Snapshot:
8.5.3 Key Financials NeoStem Inc.
8.5.4 Key Strategies NeoStem Inc.

8.5.4.1 Primary Strategies: Clinical Trials
8.5.4.2 Secondary Strategies: Collaboration

8.5.5 SWOT AnalysisofNeoStem Inc.

8.6 Geron Corporation

8.6.1 Company Overview
8.6.2 Company Snapshot:
8.6.3 Key Financials Geron Corporation
8.6.4 Key Strategies Geron Corporation

8.6.4.1 Primary Strategies: Clinical Trials and Investment
8.6.4.2 Secondary Strategies: Collaboration

8.6.5 SWOT Analysis of Geron Corporation

8.7 Opexa Therapeutics, Inc.

8.7.1 Company Overview
8.7.2 Company Snapshot:
8.7.3 Key Strategies Opexa Therapeutics, Inc.

8.7.3.1 Primary Strategies: Approval
8.7.3.2 Secondary Strategies: Agreement

8.7.4 SWOT Analysis of Opexa Therapeutics, Inc.

8.8 Athersys, Inc.

8.8.1 Company Overview
8.8.2 Company Snapshot:
8.8.3 Key Financials of Athersys, Inc.
8.8.4 Key Strategies Athersys, Inc.

8.8.4.1 Primary Strategies: Clinical Trials
8.8.4.2 Secondary Strategies: Collaboration

8.8.5 SWOT Analysis Athersys, Inc.

8.9 Pluristem Therapeutics Inc.

8.9.1 Company Overview
8.9.2 Company Snapshot:
8.9.3 Key FinancialsPluristem Therapeutics Inc.
8.9.4 Key Strategies Pluristem Therapeutics Inc.

8.9.4.1 Primary Strategies: Approval& Clearance
8.9.4.2 Secondary Strategies: Product Launch

8.9.5 SWOT Analysis of Pluristem Therapeutics Inc.

8.10 Mesoblast Limited

8.10.1 Company Overview
8.10.2 Company Snapshot:
8.10.3 Key Financials of Mesoblast Limited
8.10.4 Key Strategies of Mesoblast Limited

8.10.4.1 Primary Strategies: Acquisition
8.10.4.2 Secondary Strategies: Approval
8.10.5 SWOT Analysis ofMesoblast Limited

 

LIST OF TABLES:

TABLE 1    UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 2    DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOOD
TABLE 3   CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETES
TABLE 4    UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLION
TABLE 5    PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANK
TABLE 6    PRICING STRUCTURE OF PARENT’S GUIDE TO CORD BLOOD FOUNDATION
TABLE 7    UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLION
TABLE 8    PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKS
TABLE 9    UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLION
TABLE 10    NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)
TABLE 11    EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)
TABLE 12    UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 13    UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 14    UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 15    UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 16    GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 17    GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 18    GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 19    UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 20    GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 21    GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 22    GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 23    UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 24    UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 25    UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 26    UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 27    GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 28    GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 29    GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 30    GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 31    GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 32    GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 33    GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 34    GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLION
TABLE 35    GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 36    GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 37    GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 38    GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 39    GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 40    GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 41    GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 42    GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 43    GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 44    GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 45    GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 46    UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLION
TABLE 47    GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLION
TABLE 48    GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 49    GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLION
TABLE 50    GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 51    GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 52    GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 53    GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLION
TABLE 54    GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 55    GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 56    COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHY
TABLE 57    UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 58    CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOT
TABLE 59    ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOT
TABLE 60    CALIFORNIA STEM CELL INC. COMPANY SNAPSHOT
TABLE 61    OSIRIS THERAPEUTICS COMPANY SNAPSHOT
TABLE 62    NEOSTEM INC COMPANY SNAPSHOT
TABLE 63    GERON CORPORATION COMPANY SNAPSHOT
TABLE 64    OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 65    ATHERSYS INC. COMPANY SNAPSHOT
TABLE 66    PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOT
TABLE 67    MESOBLAST LIMITED COMPANY SNAPSHOT

 

LIST OF FIGURES:

FIG. 1    SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)
FIG. 2    UCB STEM CELL MARKET DEFINITION
FIG. 3    PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)
FIG. 4    FACTORS IMPACTING ON UCB STEM CELL MARKET
FIG. 5    TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013
FIG. 6    TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)
FIG. 7    PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKET
FIG. 8    PERCENTAGE COMPARISON OF  CAGR IN STORAGE SERVICE MARKET
FIG. 9    CORD BLOOD STEM CELL COLLECTION PROCEDURE
FIG. 10    KEY PATENTS FOR UCB STEM CELL FROM 2008-2013
FIG. 11    PATENT ANALYSIS FROM 2008-2013
FIG. 12    VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKET
FIG. 13    PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKET
FIG. 14    IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKET
FIG. 15    CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)
FIG. 16    GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)
FIG. 17    AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIES
FIG. 18    TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 19    CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 20    SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)
FIG. 21    CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)
FIG. 22    NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)
FIG. 23    TREATMENT THERPAIES ON DIABETES, 2011
FIG. 24    PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)
FIG. 25    GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 &ESTIMATED PREVALENCE IN 2030
FIG. 26    SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)
FIG. 27    STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARS
FIG. 28    IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKET
FIG. 29    EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012
FIG. 30    TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATION
FIG. 31    GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)
FIG. 32    U.S. FEDRAL SPENDING -FISCAL YEAR 2012
FIG. 33    CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMS
FIG. 34    TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIES
FIG. 35    DISEASES FACED OR IN FAMILY MEMBERS IN CHINA
FIG. 36    SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.
FIG. 37    SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)
FIG. 38    SWOT ANALYSIS OF CALIFORNIA STEM CELL
FIG. 39    SWOT ANALYSIS OSIRIS THERAPEUTICS
FIG. 40    SWOT ANALYSISOFNEOSTEM INC.
FIG. 41    SWOT ANALYSISOFGERONCORPORATION
FIG. 42    SWOT ANALYSIS OF OPEXA THERAPEUTICS, INC
FIG. 43    SWOT ANALYSIS OF ATHERSYS, INC.
FIG. 44    SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.
FIG. 45    SWOT ANALYSIS FOR MESOBLAST LIMITED

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Cord blood stem cell collection is much easier way of obtaining stem cell as compared to other stem cells such as Bone Marrow. Minimal invasive technique in stem cell collection and transferring is yet to saturate as this market is emerging in therapeutics. Minimal invasive techniques are available for collection of cord blood however; there is need to conduct some surgical operation in transferring of stem cells. These techniques are expected to become non-invasive in future.


This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SIMILAR MARKET STUDIES

Published Reports

Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells.
30 Jun 2014 | Price: $4515(SU) | View Details >>

DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics.
27 2014 | Price: $4515(SU) | View Details >>

Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. Its a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period.
27 May 2014 | Price: $4515(SU) | View Details >>

The bioinformatics market is expected to grow to $12.86 billion by 2020 with a CAGR of 21.2% during 2014-2020. Bioinformatics is an interdisciplinary field that is used in the development and storage of data, thus helping in the analysis, organization and retrieval of the biological data. Bioinformatics has various applications and thus forms part of almost all the fields in biology. Bioinformatics form a part of agriculture, animal breeding, molecular medicine, preventive medicine, etc. The major factors driving the bioinformatics market is the need for integrated data, rising demand for drug development and discovery, the increasing focus in genomics & proteomics and the favorable government initiatives.
28 May 2014 | Price: $4515(SU) | View Details >>

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market.
10 Jun 2014 | Price: $4515(SU) | View Details >>

Upcoming Reports

Identification documents and PIN are traditional methods used to verify the identity of a human being. However, an increasing number of cases of security threats, illegal transactions at ATMs, unauthorised immigration and unauthorised infiltration across borders are factors which have resulted in the evolution of new generation biometrics methods. New generation biometrics refers to technologies that are used to verify the identity of individuals through biological characteristics such as facial expression, voice, palm, fingerprints, signature, iris, vein and DNA.
Price: $4515 | Pre Book Price: $4515 | View Details >>

STDs are sexually transmitted infections generally known as sexually transmitted diseases (STD) or venereal diseases. These are illness transmitted between humans as a result of sexual behavior. A variety of methods have been employed for the identification and assessment of these diseases based on their types. Some of the commonly known types of STDs are Gonorrhea, Syphilis and HIV AIDS. The objective of this report is to provide an in-depth understanding of the market scenario of diagnostic testing of STDs.
Price: $4515 | Pre Book Price: $4515 | View Details >>

Tissue engineering is the combination of biology medicine and engineering to create products that would improve or replace biological functions or organs. More than a decade ago, the industry introduced the first FDA approved tissue-engineering product, which was a skin substitute product. These products provide natural regeneration of tissues or cells, and hence are highly effective. The medical biotechnology industry was estimated to be $160 billion in 2012.The major drivers in this industry are chronic wound and orthopedic application segment.
Price: $4515 | Pre Book Price: $4515 | View Details >>

Cardiac Biomarkers are protein substances released into the blood stream from damaged heart muscles. These are the biological parameters that are used to detect the presence of cardiovascular diseases. According to World Health Organization, in 2008, 17.3 million people died due to cardiovascular diseases and it is expected to reach 23.3 million by 2030. This increase in cardiovascular diseases across the globe widens the global cardiac biomarkers market. With the prevalence of these cardiovascular diseases, demand for cardiac biomarkers would increase in future for early diagnosis and disease management.
Price: $4515 | Pre Book Price: $4515 | View Details >>

The endocrine system comprises of the endocrine glands such as the pituitary, thyroid, pancreas, adrenal, etc. These glands secrete hormones that regulate the bodys metabolism, growth, sexual development and function. Endocrine tests help in assessing the normal functioning of the endocrine gland by checking the hormone levels. The tests detect the imbalance in hormonal levels. The various tests, their advantages and uses are described in the report. The endocrine testing market is driven by the increasing incidences of endocrine disorders such as diabetes, thyroid disorders, infertility, etc.
Price: $4515 | Pre Book Price: $4515 | View Details >>
First time Buyer ?
Check offer and
discount on this report


Get Discount

NEED MORE INFORMATION?
Call
+1 617 674 4143


Purchase Enquiry

PURCHASE OPTIONS

Single User
By obtaining a Single User License, you and your organization concur that only an individual uses this report either electronically or online. The right to use or stockpiling of the report should be confined only to one authorized computer. User will have authorization to print one duplicate of the report for individual use, yet may not be replicated for circulation. Additional copies for this report may also be order at discounted price for use by addition readers/users.
$4515

Multi User 
Multi-User license permits you to access the report from eight authorized computers. It does not permit you to display it on your company website and permits you to only print 5 copies of the report that shall not be reproduced for circulation.
$7515

Corporate  
With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report in is prohibited without the prior permission of Allied Market Research. The publisher will, in turn, regard the privacy of the purchaser and will keep it confidential. Upon buying single or multi-user license, buyer must provide the names and email ids of the authorized users of this report.
$10515


Not Interested in buying complete report?
To check the cost of chapters

WHY ALLIED MARKET RESEARCH?
INFALLIBLE METHODOLOGY
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader






Top